Richard D. Scheyer
Profile
Richard D.
Scheyer worked as a Senior Director-Phase 2b/3 Programs at Sanofi, Director-Clinical Discovery & Human Pharmacology at Aventis Pharmaceuticals, Inc. and Hoechst Marion Roussel, Inc., Director at International Serious Adverse Event Consortium, Chief Medical Officer & Vice President at Neurotrope, Inc., and Vice President-Medical Affairs at Medpace, Inc. He also worked as an Associate Professor at Yale University.
Scheyer received his undergraduate degree from Stanford University and his doctorate from SUNY Upstate Medical University.
Former positions of Richard D. Scheyer
| Companies | Position | End |
|---|---|---|
| International Serious Adverse Event Consortium | Director/Board Member | - |
Medpace, Inc.
 Medpace, Inc. Miscellaneous Commercial ServicesCommercial Services Medpace, Inc. provides clinical research services to the pharmaceutical, biotech and medical industries. It offers clinical operations, medical writing, biometrics, regulatory affairs, quality assurance, imaging core lab medical device and risk based monitoring services. The company was founded by August James Troendle in July 1992 and is headquartered in Cincinnati, OH. | Chief Tech/Sci/R&D Officer | - |
| SANOFI | Corporate Officer/Principal | - |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | - |
| Hoechst Marion Roussel, Inc. | Corporate Officer/Principal | - |
Training of Richard D. Scheyer
| Stanford University | Undergraduate Degree |
| SUNY Upstate Medical University | Doctorate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 1 |
|---|---|
| SANOFI | Health Technology |
| Private companies | 5 |
|---|---|
Neurotrope, Inc.
 Neurotrope, Inc. Pharmaceuticals: MajorHealth Technology Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY. | Health Technology |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
Medpace, Inc.
Medpace, Inc. Miscellaneous Commercial ServicesCommercial Services Medpace, Inc. provides clinical research services to the pharmaceutical, biotech and medical industries. It offers clinical operations, medical writing, biometrics, regulatory affairs, quality assurance, imaging core lab medical device and risk based monitoring services. The company was founded by August James Troendle in July 1992 and is headquartered in Cincinnati, OH. | Commercial Services |
| Hoechst Marion Roussel, Inc. | |
| International Serious Adverse Event Consortium |
- Stock Market
- Insiders
- Richard D. Scheyer
